Acrivon Therapeutics Inc [ACRV] stock prices are up 0.99% to $2.05 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ACRV shares have gain 9.63% over the last week, with a monthly amount drifted -11.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On September 16, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $16 on the stock. Ladenburg Thalmann downgraded its rating to a Neutral. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $14 as its price target on March 01, 2024. In a note dated October 05, 2023, Maxim Group initiated an Buy rating.
The stock price of Acrivon Therapeutics Inc [ACRV] has been fluctuating between $1.05 and $8.00 over the past year. Currently, Wall Street analysts expect the stock to reach $21.83 within the next 12 months. Acrivon Therapeutics Inc [NASDAQ: ACRV] shares were valued at $2.05 at the most recent close of the market. An investor can expect a potential return of 964.88% based on the average ACRV price forecast.
Analyzing the ACRV fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -0.54 and Total Capital is -0.68. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Acrivon Therapeutics Inc [NASDAQ:ACRV]’s Current Ratio is 8.75. Further, the Quick Ratio stands at 8.75, while the Cash Ratio is 2.38.
Transactions by insiders
Recent insider trading involved Blume-Jensen Peter, President and CEO, that happened on Jan 14 ’26 when 49000.0 shares were purchased. Chief Financial Officer, Levy Adam D. completed a deal on Jan 14 ’26 to buy 8832.0 shares. Meanwhile, Chief Operating Officer Devroe Eric bought 10000.0 shares on Jan 13 ’26.
